Skip to main content
Top
Published in: Journal of Nuclear Cardiology 1/2017

01-02-2017 | CME Article Review Article

Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation

Authors: Michael T. Osborne, MD, Edward A. Hulten, MD, MPH, Venkatesh L. Murthy, MD, PhD, Hicham Skali, MD, Viviany R. Taqueti, MD, MPH, Sharmila Dorbala, MD, MPH, Marcelo F. DiCarli, MD, Ron Blankstein, MD

Published in: Journal of Nuclear Cardiology | Issue 1/2017

Login to get access

Abstract

Although the number of clinical applications for fluorine-18 fluorodeoxyglucose (18F-FDG) cardiac positron emission tomography (PET) has continued to grow, there remains a lack of consensus regarding the ideal method of suppressing normal myocardial glucose utilization for image optimization. This review describes various patient preparation protocols that have been used as well as the success rates achieved in different studies. Collectively, the available literature supports using a high-fat, no-carbohydrate diet for at least two meals with a fast of 4-12 hours prior to 18F-FDG PET imaging and suggests that isolated fasting for less than 12 hours and supplementation with food or drink just prior to imaging should be avoided. Each institution should adopt a protocol and continuously monitor its effectiveness with a goal to achieve adequate myocardial suppression in greater than 80% of patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Blankstein R, Lundbye J, Heller G. Proceedings of the ASNC cardiac PET summit meeting, May 12 2014, Baltimore MD. J Nucl Cardiol 2015;22:720–9.CrossRefPubMed Blankstein R, Lundbye J, Heller G. Proceedings of the ASNC cardiac PET summit meeting, May 12 2014, Baltimore MD. J Nucl Cardiol 2015;22:720–9.CrossRefPubMed
2.
go back to reference Cautela J, Alessandrini S, Cammilleri S, Giorgi R, Richet H, Casalta JP, et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: A pilot study. Europace 2013;15:252–7.CrossRefPubMed Cautela J, Alessandrini S, Cammilleri S, Giorgi R, Richet H, Casalta JP, et al. Diagnostic yield of FDG positron-emission tomography/computed tomography in patients with CEID infection: A pilot study. Europace 2013;15:252–7.CrossRefPubMed
3.
go back to reference Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: Increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374–82.CrossRefPubMed Saby L, Laas O, Habib G, Cammilleri S, Mancini J, Tessonnier L, et al. Positron emission tomography/computed tomography for diagnosis of prosthetic valve endocarditis: Increased valvular 18F-fluorodeoxyglucose uptake as a novel major criterion. J Am Coll Cardiol 2013;61:2374–82.CrossRefPubMed
4.
go back to reference Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;21:166–74. Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;21:166–74.
5.
go back to reference Morooka M, Moroi M, Ito K, Wu J, Nakagawa T, Kubota K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesion of cardiac sarcoidosis. EJNMMI Res 2014;4:1.CrossRefPubMedPubMedCentral Morooka M, Moroi M, Ito K, Wu J, Nakagawa T, Kubota K, et al. Long fasting is effective in inhibiting physiological myocardial 18F-FDG uptake and for evaluating active lesion of cardiac sarcoidosis. EJNMMI Res 2014;4:1.CrossRefPubMedPubMedCentral
6.
go back to reference Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244–52.CrossRefPubMed Manabe O, Yoshinaga K, Ohira H, Masuda A, Sato T, Tsujino I, et al. The effects of 18-h fasting with low-carbohydrate diet preparation on suppressed physiological myocardial 18F-fluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016;23:244–52.CrossRefPubMed
7.
go back to reference Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med 2014;55:1629–35.CrossRefPubMed Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of 18F-FDG myocardial uptake suppression: Implications for vulnerable coronary plaque imaging. J Nucl Med 2014;55:1629–35.CrossRefPubMed
8.
go back to reference Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563–8.CrossRefPubMed Wykrzykowska J, Lehman S, Williams G, Parker JA, Palmer MR, Varkey S, et al. Imaging of inflamed and vulnerable plaque in coronary arteries with 18F-FDG PET/CT in patients with suppression of myocardial uptake using a low-carbohydrate, high-fat preparation. J Nucl Med 2009;50:563–8.CrossRefPubMed
9.
10.
go back to reference Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.PubMed Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K, et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001;42:1551–5.PubMed
11.
go back to reference Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767–74.CrossRefPubMedPubMedCentral Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M, et al. Glucose-free fatty acid cycle operates in heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767–74.CrossRefPubMedPubMedCentral
12.
go back to reference Yamada S, Kubota K, Kubota K, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6.PubMed Yamada S, Kubota K, Kubota K, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995;36:1301–6.PubMed
13.
go back to reference Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging inflammatory cardiovascular disease Circ J. 2014;78:1302–10.CrossRefPubMed Miyagawa M, Yokoyama R, Nishiyama Y, Ogimoto A, Higaki J, Mochizuki T. Positron emission tomography-computed tomography for imaging inflammatory cardiovascular disease Circ J. 2014;78:1302–10.CrossRefPubMed
14.
go back to reference Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; A comparative study using different protocols. Eur J Nucl Med 1997;24:35–41.CrossRefPubMed Bax JJ, Veening MA, Visser FC, van Lingen A, Heine RJ, Cornel JH, et al. Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; A comparative study using different protocols. Eur J Nucl Med 1997;24:35–41.CrossRefPubMed
15.
go back to reference Garfein O. Current concepts in cardiovascular physiology. Burlington: Elsevier Science; 2012. p. 565. Garfein O. Current concepts in cardiovascular physiology. Burlington: Elsevier Science; 2012. p. 565.
16.
go back to reference Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nuc Med 2015. doi:10.1097/RLU.0000000000001063. Tang R, Wang JT, Wang L, Le K, Huang Y, Hickey AJ, et al. Impact of patient preparation on the diagnostic performance of 18F-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. Clin Nuc Med 2015. doi:10.​1097/​RLU.​0000000000001063​.
17.
go back to reference Harisankar CN, Mittal BR, Agarwal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG Uptake. J Nucl Cardiol 2011;18:926–36.CrossRefPubMed Harisankar CN, Mittal BR, Agarwal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG Uptake. J Nucl Cardiol 2011;18:926–36.CrossRefPubMed
18.
go back to reference Soussan M, Brilley PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120–7.CrossRefPubMed Soussan M, Brilley PY, Nunes H, Pop G, Ouvrier MJ, Naggara N, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:120–7.CrossRefPubMed
19.
go back to reference Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286–91.CrossRefPubMed Cheng VY, Slomka PJ, Ahlen M, Thomson LE, Waxman AD, Berman DS. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial. J Nucl Cardiol 2010;17:286–91.CrossRefPubMed
20.
go back to reference Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314–9.CrossRefPubMed Kobayashi Y, Kumita S, Fukushima Y, Ishihara K, Suda M, Sakurai M. Significant suppression of myocardial 18F-fluorodeoxyglucose uptake using 24-h carbohydrate restriction and a low-carbohydrate, high-fat diet. J Cardiol 2013;62:314–9.CrossRefPubMed
21.
go back to reference Balink H, Hut E, Pol T, Flokstra FJ, Roef M. Suppression of 18F-FDG myocardial uptake using a fat-allowed, carbohydrate-restricted diet. J Nucl Med Technol 2011;39:185–9.CrossRefPubMed Balink H, Hut E, Pol T, Flokstra FJ, Roef M. Suppression of 18F-FDG myocardial uptake using a fat-allowed, carbohydrate-restricted diet. J Nucl Med Technol 2011;39:185–9.CrossRefPubMed
22.
go back to reference Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140–5.CrossRefPubMedPubMedCentral Kumar P, Patel CD, Singla S, Malhotra A. Effect of duration of fasting and diet on the myocardial uptake of fluoro-2-deoxyglucose (F-18 FDG) at rest. Indian J Nucl Med 2014;29:140–5.CrossRefPubMedPubMedCentral
23.
go back to reference Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet. Eur Radiol 2012;22:2221–8.CrossRefPubMed Coulden R, Chung P, Sonnex E, Ibrahim Q, Maguire C, Abele J. Suppression of myocardial 18F-FDG uptake with a preparatory “Atkins-style” low-carbohydrate diet. Eur Radiol 2012;22:2221–8.CrossRefPubMed
24.
go back to reference Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional heparin pre-administration improves cardiac glucose metabolism over low carbohydrate diet alone in 18F-FDG-PET imaging. J Nucl Med 2016;57:568–73.CrossRefPubMed Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional heparin pre-administration improves cardiac glucose metabolism over low carbohydrate diet alone in 18F-FDG-PET imaging. J Nucl Med 2016;57:568–73.CrossRefPubMed
25.
go back to reference Lum DP, Wandell S, Ko J, Koel MN. Reduction of myocardial 2-deoxy-2[18F]fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232–7.CrossRefPubMed Lum DP, Wandell S, Ko J, Koel MN. Reduction of myocardial 2-deoxy-2[18F]fluoro-d-glucose uptake artifacts in positron emission tomography using dietary carbohydrate restriction. Mol Imaging Biol 2002;4:232–7.CrossRefPubMed
26.
go back to reference Lee HY, Nam HY, Shin SK. Comparison of myocardial F-18 uptake between overnight and non-overnight fasting in non-diabetic healthy subjects. Jpn J Radiol 2015;33:385–91.CrossRefPubMed Lee HY, Nam HY, Shin SK. Comparison of myocardial F-18 uptake between overnight and non-overnight fasting in non-diabetic healthy subjects. Jpn J Radiol 2015;33:385–91.CrossRefPubMed
27.
go back to reference Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531–3.CrossRefPubMedPubMedCentral Asmal AC, Leary WP, Thandroyen F, Botha J, Wattrus S. A dose-response study of the anticoagulant and lipolytic activities of heparin in normal subjects. Br J Clin Pharmacol 1979;7:531–3.CrossRefPubMedPubMedCentral
28.
go back to reference Gaeta C, Fernández Y, Pavía J, et al. Reduced myocardial 18F-FDG uptake after calcium channel blocker administration: Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging 2011;38:2018–24.CrossRefPubMed Gaeta C, Fernández Y, Pavía J, et al. Reduced myocardial 18F-FDG uptake after calcium channel blocker administration: Initial observation for a potential new method to improve plaque detection. Eur J Nucl Med Mol Imaging 2011;38:2018–24.CrossRefPubMed
29.
go back to reference Japanese Society of Sarcoidosis and Other Granulomatous Disorders. Diagnostic standard and guideline for sarcoidosis. Tokyo: Japanese Ministry of Health, Labour and Welfare; 2006. p. 6. Japanese Society of Sarcoidosis and Other Granulomatous Disorders. Diagnostic standard and guideline for sarcoidosis. Tokyo: Japanese Ministry of Health, Labour and Welfare; 2006. p. 6.
30.
go back to reference Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578–83.CrossRefPubMed Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578–83.CrossRefPubMed
31.
go back to reference Patel MR, Cawley PC, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.CrossRefPubMedPubMedCentral Patel MR, Cawley PC, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969–77.CrossRefPubMedPubMedCentral
32.
go back to reference Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485–507.CrossRefPubMed Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V, et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485–507.CrossRefPubMed
33.
go back to reference Vik-Mo H, Mjøs OD. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol 1981;2:361–5.CrossRef Vik-Mo H, Mjøs OD. Influence of free fatty acids on myocardial oxygen consumption and ischemic injury. Am J Cardiol 1981;2:361–5.CrossRef
Metadata
Title
Patient preparation for cardiac fluorine-18 fluorodeoxyglucose positron emission tomography imaging of inflammation
Authors
Michael T. Osborne, MD
Edward A. Hulten, MD, MPH
Venkatesh L. Murthy, MD, PhD
Hicham Skali, MD
Viviany R. Taqueti, MD, MPH
Sharmila Dorbala, MD, MPH
Marcelo F. DiCarli, MD
Ron Blankstein, MD
Publication date
01-02-2017
Publisher
Springer US
Published in
Journal of Nuclear Cardiology / Issue 1/2017
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-016-0502-7

Other articles of this Issue 1/2017

Journal of Nuclear Cardiology 1/2017 Go to the issue